View full metadata
Cite as
-
Full Title
MISSION
-
Publisher
FrancoAngeli
-
ISSN
2037-4798 (Printed Journal)
-
Journal Issue Number
54
-
Journal Issue Designation
54
-
Journal Issue Date (YYYY/MM)
2020/12
-
Full Title
Approccio integrato per la gestione di pazienti con disturbi psichiatrici-tabagisti tra U.O. CSM Catanzaro e Centro Antifumo - S.S. Ser.D. Soverato
-
By (author)
-
Language of text
Italian
-
Publication Date
2020/12
-
Copyright
2020 FrancoAngeli srl
Introduction or preface
The use of tobacco is one of the major social and health problems of our times, the leading cause of preventable death.The steady reduction in the prevalence of smoking in the general population in recent decades has not been observed in populations with psychiatric disorders.Hence a pilot project that aims to promote a territorial network between the Mental Health Services and the Anti-Smoking Centers for a global intervention strategy to combat smoking in patients with psychiatric disorders trying to create conditions of "Tobacco Services-Free", including employees, at any point inside and outside the structure.The experience made with a Protocol is particularly significant in the first place to dispel the clichés on the problem of smoking and mental illness in accordance with the scientific data present in the literature.The treatment of these patients can be successful if psychiatric services in addressing the problem offer behavioral motivational support to their patients.Collaboration with specialist Centers is essential for the treatment of addiction.Varenicline was effective in helping patients achieve abstinence or reduce the number of cigarettes smoked, and did not show a significant increase in neuropsychiatric adverse events.It is desirable that all Mental Health Services be able to carry out informational-motivational counseling onsmoking-related risks, favoring access for motivated patients to specific cessation programs in collaboration with specialized services (Anti-Smoking Centers).
Reference list of
10.3280/mis54-2020oa10864
Unstructured Citation
Anthenelli R.M., Morris C., Ramey T.S. et al. (2013). Effects of varenicline on smoking cessation in adult with stably treated
current or past major depression: a randomized trial. Ann Intern Med, 159: 390-400.
https://doi.org/10.7326/0003-4819-159-6-201309170-00005
Unstructured Citation
Cahill K., Stevens R., Lancaster T. (2013). Farmacological interventions for smoking cessation: an overview and network meta-analysis.
Cochrane Database Syst Rev, 5: CD009329.
https://doi.org/10.1002/14651858.CD009329.pub2
Unstructured Citation
Evins A.E., Cather C., Pratt S.A. et al. (2014). Maintenance treatment with varenicline for smoking cessation in patients
with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA, 311: 145-54.
https://doi.org/10.1001/jama.2013.285113
Unstructured Citation
Gibbons R.D., Mann J.J. (2013). Varenicline, smoking cessation, and neuropsychiatric adverse events. Amk J Psychiatry, 170:
1460-67.
https://doi.org/10.1176/appi.ajp.2013.12121599
Unstructured Citation
Lugoboni F., Chiamulera C. (2013). Figli di un Dia assente. La dannazione del fumo tra i malati di mente. Tabaccologia, 4: 7-9.
Unstructured Citation
Molero Y., Lichtenstein P., Zetterqvist J., Gumpert C.H., Fazel S. (2015). Varenicline and risk of psychiatric conditions,
suicidal behaviors, criminal offending, and transport accidents and offences: population based cohort study. BMJ, 350: h2388.
https://doi.org/10.1136/bmj.h2388
Unstructured Citation
Pasternak B., Svanstrom H., Hviid A. (2013). Use of varenicline versus bupropion and risk of psychiatric adverse event. Addiction,
108: 1336-43.
https://doi.org/10.1111/add.12165
Unstructured Citation
Thomas K.H., Martin R.M., Knipe D.W., Higgins J.P., Gunnell D. (2015). Risk of neuropsychiatric adverse events associated
with varenicline: systematic review and meta-analysis. BMJ, 350: h1109.
https://doi.org/10.1136/bmj.h1109
Unstructured Citation
Thomas K.H., Martin R.M., Davies N.M., Metcalfe C., Windmeijer F., Gunnell D. (2013). Smoking cessation treatment and risk
of depression, suicide, and self harm in the Clinical Pratice Research Datalink: prospective cohort study. BMJ, 347: f5704.
https://doi.org/10.1136/bmj.f5704
Unstructured Citation
Vegliach A., Jugovac D., Quartarone Generoso G., Ciarfeo Purich R. (2015). Tabagismo e riduzione del danno. Tabaccologia, 1: 18-19.
Unstructured Citation
Yousefi M.K., Folsom T.D., Fatemi S.H. (2011). A review of varenicline’s efficacy and tolerability in smoking cessation studies
in subjects with schizophrenia. J Addict Res Ther, S 4.
https://doi.org/10.4172/2155-6105.S4-001